WCC_CC-5013-NHL-008

A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCY VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is an immunomodulatory agent with direct and immune-mediated mechanisms of action, as well as clinical activity in NHL. Recent studies in frontline and relapsed/refractory NHL show high acitivity for lenalidomide plus rituximab (R2), supporting further study of this combination.
Phase IIIb
NCT01996865
Cancer, All Other
Hematologic
James Cunningham, M.D.
Celgene Corporation
Cheryl Dodd
  • Providence St. Mary Regional Cancer Center
  • Walla Walla Research